Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

Video

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Yung-Jue Bang, MD, PhD, Professor of Medical Oncology, Seoul National University College of Medicine, President, Biomedical Research Institute, Seoul National University Hospital, discusses pembrolizumab for the treatment of advanced gastric cancer.

Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

The study is ongoing, and participants in the gastric cancer cohort are receiving pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and will continue to receive the drug until disease progression, death, withdrawal of consent, or up until they’ve been on treatment for 2 years.

Previously, gastric cancer was not thought to respond to immunotherapeutic agents like pembrolizumab, said Bang. However durable efficacy has been seen in gastric cancer in the study. The results are surprising, but very promising for the future of immunotherapy in gastric cancer, said Bang.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center